FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.664,17 +438,51 (+1,15%) Nasdaq
16.152,77 +311,82 (+1,97%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,39 -0,56 (-0,71%) Bitcoin EUR
57.442,80 +2.470,64 (+4,49%)
Crinetics Pharmaceuticals, Inc. (CRNX)
| Chiusura precedente | 46,78 |
| Aperto | 47,52 |
| Denaro | 47,48 x 100 |
| Lettera | 47,67 x 100 |
| Min-Max giorno | 47,13 - 48,37 |
| Intervallo di 52 settimane | 15,76 - 49,58 |
| Volume | |
| Media Volume | 811.159 |
| Capitalizzazione | 3,753B |
| Beta (5 anni mensile) | 0,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,69 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 57,92 |
GlobeNewswireCrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on October 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-ex
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023Time: 1:00 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the
- GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
